US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Neurogene Inc. - Common Stock (NQ:NGNE)

26.47 +0.82 (+3.20%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurogene Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Neurogene Announces Addition to Russell 3000® Index
From Neurogene Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
MicroMarvel Neurogene Challenges Big Pharma ↗
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. 
Via Talk Markets
News headline image
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Upcoming Conferences
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
From Neurogene Inc.
Via Business Wire
News headline image
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 ↗
NGNE stock results show that Neurogene beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
From Neurogene Inc.
Via Business Wire
News headline image
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 ↗
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades. 
Via InvestorPlace
News headline image
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Upcoming Investor Conferences
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Business Update and 2024 Outlook
From Neurogene Inc.
Via Business Wire
< Previous 1 2 3 4 Next >